Australian Pharmaceutical Industries Ltd

Australian Pharmaceutical Industries Ltd

Consumer ServicesFood & Drug Retailers
  • Price (AUD)1.42
  • Today's Change0.02 / 1.43%
  • Shares traded2.18m
  • 1 Year change-8.12%
  • Beta1.2140
Data delayed at least 20 minutes, as of Mar 18 2019 05:10 BST.
More ▼

Profile data is unavailable for this security.

About the company

Australian Pharmaceutical Industries Limited is a pharmaceutical distributor, and health and beauty retailer. The Company operates through two segments: Australia, which is engaged in the distribution of pharmaceutical, medical, health, beauty and lifestyle products to pharmacies, the purchase and sale of various health, beauty and lifestyle products within the retail industry, and the provision of retail services to pharmacies, and New Zealand, which manufactures and owns rights of pharmaceutical medicines and consumer toiletries. Its services include wholesale product delivery, retail services, marketing programs and business advisory services. Its brands include Priceline & Priceline Pharmacy, which is a health, beauty and wellbeing retailer; Soul Pattinson Chemist, which is a pharmacy brand; Pharmacist Advice, which offers professional service and advice; Club Premium, which is a club for independent pharmacies, and Pharmacy Best Buys, which offers a catalog program.

  • Revenue in AUD (TTM)4.04bn
  • Net income in AUD48.06m
  • Incorporated1910
  • Employees5.11k
  • Location
    Australian Pharmaceutical Industries LtdL 5 250 Camberwell RdMELBOURNE 3124AustraliaAUS
  • Phone+61 38855-3000
  • Fax+61 38855-3401
  • Websitehttp://www.api.net.au/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
API:ASX since
Sigma Healthcare LtdAnnounced14 Dec 201814 Dec 2018Announced-3.74%457.15m
Clearskincare Clinics Pty Ltd-Clinic BusinessDeal completed25 Jun 201825 Jun 2018Deal completed4.04%94.77m
Clearskincare Clinics Pty Ltd-Skincare Products BusinessDeal completed25 Jun 201825 Jun 2018Deal completed4.04%--
Data delayed at least 20 minutes, as of Mar 18 2019 05:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Apex Healthcare Berhad225.00m20.20m377.24m1.18k18.682.8316.071.680.49780.49785.553.281.316.544.36--11.7710.0915.4213.3323.7722.758.997.171.97--0.071832.715.229.3031.7714.3011.1711.03
Genky DrugStores Co Ltd1.27bn40.24m479.86m810.0011.931.516.020.3786205.45205.456,472.301,619.831.715.31122.52123,663,800.005.445.228.809.2523.1722.393.172.900.1861219.280.418110.2413.7511.669.5838.009.900.00
Shanghai No.1 Pharmacy Co Ltd260.09m7.51m517.44m934.0068.883.76--1.990.16030.16035.552.931.094.549.291,325,422.003.163.724.675.4418.6515.702.892.761.34--0.032932.032.442.77-5.563.60-24.233.71
CAWACHI LTD.3.37bn45.23m575.21m2.60k11.800.44975.310.1709156.64156.6411,660.294,112.001.416.5271.59102,398,800.001.900.74412.891.1121.6021.301.340.51660.624106.530.254577.240.66892.9710.2313.371.782.38
Yakuodo Co Ltd1.14bn38.85m659.76m653.0016.982.7710.490.5801155.52155.524,552.83953.232.295.26211.22137,632,500.007.826.9713.6111.8923.3922.943.422.810.1996--0.257615.5010.9311.6825.0220.5811.4019.14
Australian Pharmaceutical Industries Ltd4.04bn48.06m687.08m5.11k14.361.35--0.17030.09720.09728.161.032.738.886.04--3.261.507.413.4012.5312.681.190.55770.847811.090.1565133.77-0.78654.97-8.2414.620.473618.20
Qol Holdings Co Ltd1.81bn50.12m715.80m4.68k14.091.477.050.3948103.17103.173,731.65986.701.6118.647.9930,625,480.004.444.917.128.5312.5212.352.772.621.17--0.388524.4910.6613.6414.5429.88-5.697.63
NIHON CHOUZAI Co.,Ltd.3.09bn43.76m800.97m4.08k17.901.495.790.259220.70220.7015,465.382,655.441.336.0510.1259,982,330.001.883.003.105.1416.9417.431.422.110.626311.970.665715.097.9711.5931.61101.4517.207.39
HPGC Renmintongtai Pharmaceutical Corp1.48bn54.18m850.39m2.48k15.702.56--0.57370.44470.444712.172.721.526.902.762,841,410.005.574.2014.7810.0912.4812.633.652.481.1416.190.216354.56-11.9117.301.44109.03-29.53--
Data as of Mar 18 2019. Currency figures normalised to Australian Pharmaceutical Industries Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

23.93%Per cent of shares held by top holders
HolderShares% Held
Colonial First State Asset Management (Australia) Ltd.as of 16 Oct 201825.19m5.12%
LSV Asset Managementas of 19 Dec 201824.83m5.04%
Dimensional Fund Advisors LPas of 31 Dec 201817.07m3.47%
Investors Mutual Ltd.as of 31 Jan 201914.73m2.99%
Norges Bank Investment Managementas of 31 Dec 201712.54m2.55%
The Vanguard Group, Inc.as of 31 Jan 201910.29m2.09%
Vanguard Investments Australia Ltd.as of 31 Jan 20194.70m0.96%
BlackRock Fund Advisorsas of 07 Mar 20193.86m0.79%
Jackson National Asset Management LLCas of 31 Dec 20182.32m0.47%
Charles Schwab Investment Management, Inc.as of 07 Mar 20192.30m0.47%
More ▼
Data from 31 Dec 2017 - 31 Jan 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.